Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to determine the time interval following the last
treatment dose of enoxaparin at which the amount of anti-Xa level activity is reliably less
than 0.2IU/mL in patients presenting for elective surgery.